Ventricular ejection fraction over time in patients on intensive home hemodialysis: A retrospective cohort study

Abstract Background Protection afforded from prior disease among patients with coronavirus disease 2019 (COVID-19) infection is unknown. If infection provides substantial long-lasting immunity, it may be appropriate to reconsider vaccination distribution. Methods This retrospective cohort study of 1 health system included 150 325 patients tested for COVID-19 infection via polymerase chain reaction from 12 March 2020 to 30 August 2020. Testing performed up to 24 February 2021 in these patients was included. The main outcome was reinfection, defined as infection ≥90 days after initial testing. Secondary outcomes were symptomatic infection and protection of prior infection against reinfection. Results Of 150 325 patients, 8845 (5.9%) tested positive and 141 480 (94.1%) tested negative before 30 August. A total of 1278 (14.4%) positive patients were retested after 90 days, and 62 had possible reinfection. Of those, 31 (50%) were symptomatic. Of those with initial negative testing, 5449 (3.9%) were subsequently positive and 3191 of those (58.5%) were symptomatic. Protection offered from prior infection was 81.8% (95% confidence interval [CI], 76.6–85.8) and against symptomatic infection was 84.5% (95% CI, 77.9–89.1). This protection increased over time. Conclusions Prior infection in patients with COVID-19 was highly protective against reinfection and symptomatic disease. This protection increased over time, suggesting that viral shedding or ongoing immune response may persist beyond 90 days and may not represent true reinfection. As vaccine supply is limited, patients with known history of COVID-19 could delay early vaccination to allow for the most vulnerable to access the vaccine and slow transmission.

Download Full-text

Monitoring of left ventricular ejection fraction with a miniature, nonimaging nuclear detector: Accuracy and reliability over time with special reference to blood labeling☆

Journal of Nuclear Cardiology ◽

10.1016/s1071-3581(97)90064-7 ◽

1997 ◽

Vol 4 (2) ◽

pp. 147-155 ◽

Cited By ~ 2

Author(s):

T LINDHARDT ◽

B HESSE ◽

N GADSBOLL

Keyword(s):

Left Ventricular Ejection Fraction ◽

Ejection Fraction ◽

Special Reference ◽

Left Ventricular ◽

Ventricular Ejection ◽

Left Ventricular Ejection ◽

Ventricular Ejection Fraction ◽

Nuclear Detector ◽

Over Time

Download Full-text

A Retrospective Cohort Study Evaluating Surgical Aptitude Over Time in a New Male-To-Female Penoscrotal Vaginoplasty Program

Journal of Sexual Medicine ◽

10.1016/j.jsxm.2020.05.032 ◽

2020 ◽

Vol 17 (9) ◽

pp. 1787-1794

Author(s):

Rachel M. Whynott ◽

Karen Summers ◽

Riley Mickelsen ◽

Satish Ponnuru ◽

Joshua A. Broghammer ◽

...

Keyword(s):

Cohort Study ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Male To Female ◽

Over Time

Download Full-text

Clinical Tolerability of Generic vs. Brand Beta Blockers in Heart Failure with Reduced Left Ventricular Ejection Fraction: A Retrospective Cohort from Heart Failure Clinic

Cardiovascular Pharmacology Open Access ◽

10.4172/2329-6607.1000208 ◽

2017 ◽

Vol 06 (02) ◽

Author(s):

Chanchai R ◽

Kanjanavanit R ◽

Leemasawat K ◽

Amarittakomol A ◽

Topaiboon P ◽

...

Keyword(s):

Heart Failure ◽

Left Ventricular Ejection Fraction ◽

Ejection Fraction ◽

Retrospective Cohort ◽

Beta Blockers ◽

Left Ventricular ◽

Ventricular Ejection ◽

Left Ventricular Ejection ◽

Ventricular Ejection Fraction ◽

Heart Failure Clinic

Download Full-text

Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records

BMJ Open ◽

10.1136/bmjopen-2019-032551 ◽

2019 ◽

Vol 9 (12) ◽

pp. e032551 ◽

Cited By ~ 2

Author(s):

Graham Powell ◽

John Logan ◽

Victor Kiri ◽

Simon Borghs

Keyword(s):

Cohort Study ◽

Clinical Practice ◽

Electronic Medical Records ◽

Retrospective Cohort Study ◽

Medical Records ◽

Retrospective Cohort ◽

First Line ◽

Nice Guideline ◽

Treatment Trends ◽

Over Time

ObjectiveTo assess the evolution of antiepileptic drug (AED) treatment patterns and seizure outcomes in England from 2003 to 2016.Design, setting and participantsRetrospective cohort study of electronic medical records from Clinical Practice Research Datalink and National Health Service Digital Hospital Episode Statistics databases. Patients newly diagnosed with epilepsy were identified and followed until end of data availability. Three eras were defined starting 1 April 2003 (first National Institute for Health and Care Excellence (NICE) guideline); 1 September 2007 (Standard and New Antiepileptic Drugs publication); and 1 January 2012 (second NICE guideline).Outcome measuresTime from diagnosis to first AED; AED sequence; time from first AED to first 1-year remission period (no new AED attempts and no seizure-related healthcare events); time from first AED to refractoriness (third AED attempt regardless of reason); Kaplan-Meier analysis of time-to-event variables.Results4388 patients were included (mean follow-up: 6.8, 4.2 and 1.7 years by era). 84.6% of adults (≥16 years), 75.5% of children (<16) and 89.1% of elderly subgroup (65+) received treatment within 1 year; rates were generally stable over time. Treatment trends included reduced use of carbamazepine (adult first line, era 1: 34.9%; era 3: 10.7%) and phenytoin, earlier line and increased use of levetiracetam (adult first line, era 1: 2.6%; era 3: 26.2%) and lamotrigine (particularly in adults and elderly subgroup), and a larger number of different AEDs used. Valproate use shifted somewhat to later lines. Rates of 1-year remission within 2 years of starting treatment increased in adults (era 1: 71.9%; era 3: 81.4%) and elderly (era 1: 76.1%; era 3: 81.7%). Overall, 55.5% of patients relapsed after achieving 1-year remission. Refractoriness rates remained stable over time (~26% of adults within 5 years).ConclusionTreatment trends often were not aligned with era-relevant guidance. However, our results suggest a slight improvement in epilepsy treatment outcomes over the 13-year period.

Download Full-text

Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic

Journal of Drug Assessment ◽

10.1080/21556660.2018.1423988 ◽

2018 ◽

Vol 7 (1) ◽

pp. 8-13 ◽

Cited By ~ 1

Author(s):

Rattanachai Chanchai ◽

Rungsrit Kanjanavanit ◽

Krit Leemasawat ◽

Anong Amarittakomol ◽

Paleerat Topaiboon ◽

...

Keyword(s):

Heart Failure ◽

Left Ventricular Ejection Fraction ◽

Ejection Fraction ◽

Retrospective Cohort ◽

Beta Blockers ◽

Left Ventricular ◽

Ventricular Ejection ◽

Left Ventricular Ejection ◽

Ventricular Ejection Fraction ◽

Heart Failure Clinic

Download Full-text

Reference Percentiles and Changes over Time for Total Thyroxine in Preterm Infants: A Retrospective Cohort Study

Diagnostics ◽

10.3390/diagnostics10070475 ◽

2020 ◽

Vol 10 (7) ◽

pp. 475

Author(s):

Claudia M. Flores-Robles ◽

Ernesto Roldan-Valadez ◽

Nayeli Martínez-Cruz ◽

Lidia Arce-Sánchez ◽

Ana L. Priego-Zurita ◽

...

Keyword(s):

Cohort Study ◽

Preterm Infants ◽

Gestational Age ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Reference Ranges ◽

Screening Programs ◽

Cutoff Values ◽

Total Thyroxine ◽

Over Time

Hypothyroxinemia of prematurity increases the rate of false-positive results in total thyroxine (tT4)-based screening programs for congenital hypothyroidism. The use of specific cutoff values for preterm infants has been proposed, but data on tT4 reference ranges in this population are limited. The primary aim was to establish reference percentiles for tT4 in dried blood spots among Mexican preterm infants. Secondary aims included a comparison of the change of tT4 concentrations over time according to gestational age and to discuss its impact on tT4-based screening programs. This was a retrospective cohort study; 1561 preterm infants were included. Percentile 10th for tT4 concentration at 24–27, 28–30, 31–34, and 35–36 weeks of gestational age, measured in the first week of life was: 47.6, 56.6, 82.3, and 117.1 nmol/L, respectively. tT4 concentrations were compared in three different time points: first week of life, 2–3 weeks of life, and term-corrected gestational age (38 weeks of gestation), progressively increased in infants below 30 weeks, remained stable in infants from 31 to 34 weeks, and decreased in late preterm newborns (35–36 weeks). This study suggests that preterm infants may require the use of lower tT4 cutoff values in newborn screening.

Download Full-text